Efficacy and safety of tonabersat, a gap-junction modulator, in the acute treatment of migraine: a double-blind, parallel-group, randomized study
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Efficacy and safety of tonabersat, a gap-junction modulator, in the acute treatment of migraine: a double-blind, parallel-group, randomized study. / Dahlöf, C G H; Hauge, A W; Olesen, J; Dahlöf, C G H; Hauge, Anne Werner; Olesen, Jes.
I: Cephalalgia, Bind 29, Nr. Suppl 2, 2009, s. 7-16.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Efficacy and safety of tonabersat, a gap-junction modulator, in the acute treatment of migraine: a double-blind, parallel-group, randomized study
AU - Dahlöf, C G H
AU - Hauge, A W
AU - Olesen, J
AU - Dahlöf, C G H
AU - Hauge, Anne Werner
AU - Olesen, Jes
N1 - Keywords: Adult; Analgesics; Benzamides; Benzopyrans; Double-Blind Method; Female; Humans; Male; Migraine Disorders; Safety; Serotonin Agonists; Sumatriptan; Treatment Outcome
PY - 2009
Y1 - 2009
N2 - The ability of tonabersat to relieve the symptoms of migraine attacks with or without aura was evaluated in a randomized, double-blind, placebo-controlled, multicentre, parallel-group study. Patients received 20 or 40 mg of tonabersat, or 50 mg of sumatriptan (positive control), or placebo at the onset of a moderate or severe attack. Headache intensity, relief and recurrence were recorded for 24 h after dosing. On the basis of primary or secondary efficacy measures, tonabersat did not provide a clinically or statistically significant advantage over placebo. Tonabersat generally was well tolerated and had no effect on vital signs, electrocardiogram recordings or laboratory values. The lack of efficacy may be a function of the slow absorption of tonabersat. As a consequence of slow absorption, daily administration of tonabersat as prophylaxis for migraine attacks is under investigation in ongoing studies.
AB - The ability of tonabersat to relieve the symptoms of migraine attacks with or without aura was evaluated in a randomized, double-blind, placebo-controlled, multicentre, parallel-group study. Patients received 20 or 40 mg of tonabersat, or 50 mg of sumatriptan (positive control), or placebo at the onset of a moderate or severe attack. Headache intensity, relief and recurrence were recorded for 24 h after dosing. On the basis of primary or secondary efficacy measures, tonabersat did not provide a clinically or statistically significant advantage over placebo. Tonabersat generally was well tolerated and had no effect on vital signs, electrocardiogram recordings or laboratory values. The lack of efficacy may be a function of the slow absorption of tonabersat. As a consequence of slow absorption, daily administration of tonabersat as prophylaxis for migraine attacks is under investigation in ongoing studies.
U2 - 10.1111/j.1468-2982.2009.01975.x
DO - 10.1111/j.1468-2982.2009.01975.x
M3 - Journal article
C2 - 19723121
VL - 29
SP - 7
EP - 16
JO - Cephalalgia
JF - Cephalalgia
SN - 0800-1952
IS - Suppl 2
ER -
ID: 21405810